Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in overweight/obese ...

In the last reported quarter, the company delivered a negative earnings surprise of 22.37%, as seen in the chart below ... and weight loss medicine, Zepbound. However, in mid-January, Lilly ...

Zepbound (tirzepatide) is a prescription injection that comes as a single-dose pen or single-dose vial. If your doctor prescribes Zepbound to you and you need to travel, there are certain things ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Some peptides help promote weight loss by helping to regulate blood sugar levels, metabolism, and appetite. These medications may cause side effects and people must have a prescription to take them.